MX2009006564A - Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico. - Google Patents
Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico.Info
- Publication number
- MX2009006564A MX2009006564A MX2009006564A MX2009006564A MX2009006564A MX 2009006564 A MX2009006564 A MX 2009006564A MX 2009006564 A MX2009006564 A MX 2009006564A MX 2009006564 A MX2009006564 A MX 2009006564A MX 2009006564 A MX2009006564 A MX 2009006564A
- Authority
- MX
- Mexico
- Prior art keywords
- modified
- glucagon
- buffers
- physiological
- seq
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 5
- 239000000872 buffer Substances 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000051325 Glucagon Human genes 0.000 abstract 2
- 108060003199 Glucagon Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 229960004666 glucagon Drugs 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 abstract 1
- 229920002527 Glycogen Polymers 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 229940096919 glycogen Drugs 0.000 abstract 1
- 230000006320 pegylation Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87891907P | 2007-01-05 | 2007-01-05 | |
| PCT/US2008/050099 WO2008086086A2 (en) | 2007-01-05 | 2008-01-03 | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006564A true MX2009006564A (es) | 2009-06-26 |
Family
ID=39609306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006564A MX2009006564A (es) | 2007-01-05 | 2008-01-03 | Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8669228B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2124974B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5890085B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101578102B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008205229B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2674354A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2628063T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL199263A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009006564A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2477286C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG177953A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008086086A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2572952T3 (es) * | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
| RU2477286C2 (ru) | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| MX2009008241A (es) * | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| US8980830B2 (en) * | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
| CA2713348C (en) * | 2008-01-30 | 2018-10-09 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| WO2010011439A2 (en) | 2008-06-17 | 2010-01-28 | Indiana University Research And Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| AR072160A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| WO2009155257A1 (en) * | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| AU2009327418A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| NZ598686A (en) | 2009-09-28 | 2014-05-30 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| AU2011231503C1 (en) | 2010-03-26 | 2016-03-03 | Novo Nordisk A/S | Novel glucagon analogues |
| CN102933598A (zh) * | 2010-03-26 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
| JP6121323B2 (ja) | 2010-05-13 | 2017-05-10 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| EP2635296B1 (en) | 2010-11-03 | 2014-12-24 | Arecor Limited | Novel composition comprising glucagon |
| PE20140186A1 (es) | 2010-12-22 | 2014-02-13 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| CA2830974A1 (en) | 2011-03-28 | 2012-10-04 | Jesper F. Lau | Novel glucagon analogues |
| CN102212127B (zh) * | 2011-05-17 | 2015-02-04 | 上海景泽生物技术有限公司 | 胰高血糖素样肽-2聚乙二醇结合物及其制备方法和用途 |
| CN103649115B (zh) * | 2011-06-10 | 2016-01-20 | 诺沃—诺迪斯克有限公司 | 多肽 |
| JP6179864B2 (ja) | 2011-06-22 | 2017-08-16 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト |
| CN103748109A (zh) | 2011-06-22 | 2014-04-23 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共同激动剂 |
| US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
| TWI596110B (zh) | 2011-09-23 | 2017-08-21 | 諾佛 儂迪克股份有限公司 | 新穎升糖素類似物 |
| EP2780031B1 (en) | 2011-11-17 | 2018-03-07 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| SG11201500375PA (en) | 2012-07-23 | 2015-02-27 | Zealand Pharma As | Glucagon analogues |
| US9546205B2 (en) | 2012-09-17 | 2017-01-17 | Imperial Innovations Limited | Peptide analogues of glucagon and GLP1 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CA2895875A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 derivatives |
| WO2014158900A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| PL2986313T3 (pl) | 2013-04-18 | 2019-12-31 | Novo Nordisk A/S | Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych |
| CN119119235A (zh) | 2013-10-17 | 2024-12-13 | 西兰制药公司 | 酰化胰高血糖素类似物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| AR098614A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| AR098615A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| AR098616A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| JP2017509603A (ja) | 2014-02-18 | 2017-04-06 | ノヴォ ノルディスク アー／エス | 安定なグルカゴン類似体及び低血糖症の処置のための使用 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| EP3206710B1 (en) | 2014-09-24 | 2020-05-06 | Indiana University Research & Technology Corporation | Incretin-insulin conjugates |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| MA55068A (fr) | 2014-10-24 | 2022-01-05 | Merck Sharp & Dohme | Co-agonistes des récepteurs du glucagon et du glp-1 |
| AU2015340586B2 (en) | 2014-10-29 | 2020-04-30 | Zealand Pharma A/S | GIP agonist compounds and methods |
| CN107636009B (zh) * | 2014-12-30 | 2021-04-16 | 韩美药品株式会社 | 具有改善的稳定性的胰高血糖素衍生物 |
| KR20170137198A (ko) | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
| AU2016270984B2 (en) | 2015-06-03 | 2021-02-25 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TWI713541B (zh) | 2015-06-30 | 2020-12-21 | 南韓商韓美藥品股份有限公司 | 升糖素衍生物及包含該衍生物之長效接合物之組成物 |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| HUE059737T2 (hu) | 2015-12-31 | 2022-12-28 | Hanmi Pharm Ind Co Ltd | Glükagon, GLP-1 és GIP receptor aktiváló tripla aktivátor |
| WO2017200944A1 (en) * | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| CN105968186B (zh) * | 2016-06-02 | 2020-10-30 | 中国药科大学 | 具有长效化作用的胰高血糖素(Glu)类似物及其应用 |
| EP3468569A4 (en) * | 2016-06-09 | 2020-05-27 | AmideBio LLC | GLUCAGON ANALOGS AND METHODS OF USING THE SAME |
| GB201611077D0 (en) | 2016-06-24 | 2016-08-10 | Arecor Ltd | Novel composition |
| PE20190355A1 (es) | 2016-06-29 | 2019-03-07 | Hanmi Pharm Ind Co Ltd | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo |
| CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
| CA3067674A1 (en) * | 2017-06-29 | 2019-01-03 | Ureka Sarl | Pro-drug peptide with improved pharmaceutical properties |
| WO2020163125A1 (en) | 2019-02-05 | 2020-08-13 | Eli Lilly And Company | Glucagon analog agonists and methods of using the same |
| EP4329812A1 (en) | 2021-04-27 | 2024-03-06 | Aardvark Therapeutics Inc. | Combination of bitter receptor agonist and gut-signaling compound |
| GB202109087D0 (en) | 2021-06-24 | 2021-08-11 | Norwegian Univ Sci & Tech Ntnu | Therapeutic methods and devices |
| CN119930789A (zh) * | 2023-11-06 | 2025-05-06 | 成都奥达生物科技有限公司 | 一种gcg激动剂化合物 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275152A (en) * | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| US5539084A (en) * | 1989-02-17 | 1996-07-23 | Coselco Mimotopes Pty. Ltd. | Method for the use and synthesis of peptides |
| CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| US5510459A (en) * | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
| WO1997029180A1 (en) | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
| WO1998011126A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| WO1998024464A1 (en) | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US20030236190A1 (en) * | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| EP1119625B1 (en) | 1998-10-07 | 2005-06-29 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| DE69938669D1 (de) * | 1998-12-07 | 2008-06-19 | Sod Conseils Rech Applic | Analoge des glucagon ähnlichen peptides-1 (glp-1) |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| AU2001257278A1 (en) | 2000-04-27 | 2001-11-07 | Bionebraska, Inc. | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
| US6677136B2 (en) * | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| CA2410604A1 (en) * | 2000-06-14 | 2001-12-20 | Cytovax Biotechnologies, Inc. | Use of coiled-coil structural scaffold to generate structure-specific peptides |
| KR100847615B1 (ko) | 2000-06-16 | 2008-07-21 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드-1 유사체 |
| US20030204063A1 (en) * | 2000-08-02 | 2003-10-30 | Denis Gravel | Modified biological peptides with increased potency |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| ATE516820T1 (de) * | 2000-09-29 | 2011-08-15 | Schering Corp | Pegyliertes interleukin 10 |
| AU2002228608A1 (en) | 2000-12-13 | 2002-06-24 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
| AU2002327430A1 (en) * | 2001-08-08 | 2003-02-24 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
| WO2003020201A2 (en) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7041646B2 (en) * | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| AR036711A1 (es) * | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US7238670B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| MXPA04003569A (es) | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
| AU2002351752A1 (en) * | 2001-12-29 | 2003-07-30 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| US20060252916A1 (en) * | 2002-06-04 | 2006-11-09 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
| WO2003103697A2 (en) | 2002-06-11 | 2003-12-18 | Cell Therapeutics Scandinavia Ab | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
| CA2489323A1 (en) | 2002-06-15 | 2003-12-24 | Enteromed, Inc. | Treatment of non-alcoholic fatty liver disease |
| EP1539210A4 (en) | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE |
| US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| EP1626981A4 (en) | 2003-03-04 | 2006-11-22 | Biorexis Pharmaceutical Corp | PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE |
| JP2006520818A (ja) * | 2003-03-19 | 2006-09-14 | イーライ リリー アンド カンパニー | ポリエチレングリコール結合ｇｌｐ−１化合物 |
| CA2521784C (en) * | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| WO2004103390A2 (en) | 2003-05-15 | 2004-12-02 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| JP2007524592A (ja) * | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー／エス | 安定化された薬学的ペプチド組成物 |
| EP1633390B1 (en) | 2003-06-03 | 2012-01-18 | Novo Nordisk A/S | Stabilized pharmaceutical glp-1 peptide compositions |
| UA87458C2 (ru) * | 2003-06-12 | 2009-07-27 | Елі Ліллі Енд Компані | Гибридные белки-аналоги glp-1 |
| US20050124550A1 (en) * | 2003-06-18 | 2005-06-09 | Peri Krishna G. | Compounds that modulate the glucagon response and uses thereof |
| AU2004273573B2 (en) * | 2003-09-19 | 2010-04-22 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| US7364875B2 (en) * | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
| WO2005058954A1 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 compounds |
| US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| BRPI0606992A2 (pt) * | 2005-02-11 | 2009-07-28 | Amylin Pharmaceuticals Inc | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| EP1863537A2 (en) * | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| ATE482724T1 (de) | 2005-05-13 | 2010-10-15 | Lilly Co Eli | Pegylierte glp-1-verbindungen |
| EP1891105B1 (en) | 2005-06-13 | 2012-04-11 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| US20090286722A1 (en) | 2005-09-08 | 2009-11-19 | Utech Limited | Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function |
| ES2572952T3 (es) * | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
| AU2007221366B2 (en) | 2006-02-22 | 2012-08-23 | Msd Italia S.R.L. | Oxyntomodulin derivatives |
| EP1996224B1 (en) * | 2006-03-15 | 2012-11-07 | Novo Nordisk A/S | Mixtures of amylin and insulin |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| CN104193815A (zh) * | 2006-09-08 | 2014-12-10 | Ambrx公司 | 经修饰的人类血浆多肽或Fc骨架和其用途 |
| RU2477286C2 (ru) | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
| MX2009008241A (es) * | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| US7859468B2 (en) * | 2007-08-30 | 2010-12-28 | Research In Motion Limited | Mobile wireless communications device including a folded monopole multi-band antenna and related methods |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| EP2650006A1 (en) | 2007-09-07 | 2013-10-16 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| WO2009034117A1 (en) | 2007-09-11 | 2009-03-19 | Novo Nordisk A/S | Mixture comprising an amylin peptide and a protracted insulin |
| US8980830B2 (en) | 2007-10-30 | 2015-03-17 | Indiana University Research And Technology Corporation | Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| ES2509883T3 (es) | 2007-10-30 | 2014-10-20 | Indiana University Research And Technology Corporation | Antagonistas de glucagón |
| CA2713348C (en) | 2008-01-30 | 2018-10-09 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| HUE044174T2 (hu) | 2008-02-01 | 2019-10-28 | Ascendis Pharma As | Önhasítható linkert tartalmazó elõvegyület |
| WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| WO2010011439A2 (en) | 2008-06-17 | 2010-01-28 | Indiana University Research And Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
| AR072160A1 (es) * | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| AU2009327418A1 (en) * | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| KR20110114568A (ko) | 2008-12-19 | 2011-10-19 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 디펩티드 링크된 약효 물질 |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| US8551946B2 (en) | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| JP6121323B2 (ja) | 2010-05-13 | 2017-05-10 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| US9145451B2 (en) | 2010-05-13 | 2015-09-29 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhbiting G protein coupled receptor activity |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
-
2008
- 2008-01-03 RU RU2009129961/10A patent/RU2477286C2/ru not_active IP Right Cessation
- 2008-01-03 AU AU2008205229A patent/AU2008205229B2/en not_active Ceased
- 2008-01-03 CA CA002674354A patent/CA2674354A1/en not_active Abandoned
- 2008-01-03 ES ES08713455.7T patent/ES2628063T3/es active Active
- 2008-01-03 JP JP2009544968A patent/JP5890085B2/ja not_active Expired - Fee Related
- 2008-01-03 EP EP08713455.7A patent/EP2124974B1/en not_active Not-in-force
- 2008-01-03 CN CN2008800016731A patent/CN101578102B/zh not_active Expired - Fee Related
- 2008-01-03 MX MX2009006564A patent/MX2009006564A/es active IP Right Grant
- 2008-01-03 US US12/522,129 patent/US8669228B2/en not_active Expired - Fee Related
- 2008-01-03 WO PCT/US2008/050099 patent/WO2008086086A2/en not_active Ceased
- 2008-01-03 SG SG2012000709A patent/SG177953A1/en unknown
-
2009
- 2009-06-09 IL IL199263A patent/IL199263A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010515686A (ja) | 2010-05-13 |
| WO2008086086A2 (en) | 2008-07-17 |
| SG177953A1 (en) | 2012-02-28 |
| JP5890085B2 (ja) | 2016-03-22 |
| US8669228B2 (en) | 2014-03-11 |
| AU2008205229B2 (en) | 2014-03-27 |
| CN101578102A (zh) | 2009-11-11 |
| EP2124974A2 (en) | 2009-12-02 |
| RU2477286C2 (ru) | 2013-03-10 |
| US20100190699A1 (en) | 2010-07-29 |
| RU2009129961A (ru) | 2011-02-10 |
| AU2008205229A1 (en) | 2008-07-17 |
| IL199263A (en) | 2013-09-30 |
| EP2124974B1 (en) | 2017-03-15 |
| ES2628063T3 (es) | 2017-08-01 |
| EP2124974A4 (en) | 2010-03-31 |
| CN101578102B (zh) | 2013-07-17 |
| CA2674354A1 (en) | 2008-07-17 |
| WO2008086086A3 (en) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006564A (es) | Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico. | |
| MX2010012695A (es) | Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico. | |
| TN2009000313A1 (en) | Glucagon/glp - 1 receptor co-agonists | |
| EA019203B9 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
| NZ603811A (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases | |
| NZ590050A (en) | Fgf21 mutants and uses thereof | |
| NZ600732A (en) | Oxyntomodulin peptide analogue | |
| NZ603813A (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases | |
| NZ600731A (en) | Oxyntomodulin peptide analogue | |
| WO2007056362A3 (en) | Glucagon analogs exhibiting physiological solubility and stability | |
| NZ624533A (en) | Novel immunotherapy against several tumors including neuronal and brain tumors | |
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| NZ630484A (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| NZ704192A (en) | Cell-penetrating peptides and uses therof | |
| MX2010002001A (es) | Peptido cdca1 y agente farmaceutico que comprende elmismo. | |
| IN2014CN02050A (cg-RX-API-DMAC7.html) | ||
| MX350126B (es) | Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo. | |
| NZ606584A (en) | Binding proteins for hepcidin | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| NZ600363A (en) | Modified porcine somatotropin polypeptides and their uses | |
| MX2019008056A (es) | Agonistas del receptor pac1 (maxcaps) y usos de estos. | |
| WO2010007144A3 (en) | Mutated netrin-4 proteins, fragments thereof and their uses as drugs | |
| NZ614557A (en) | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use | |
| ZA200901342B (en) | Cytokine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |